Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 3 ( March, 2021 ) > List of Articles


Tocilizumab in COVID-19: Is the Temptation Worthwhile?

Citation Information : Tocilizumab in COVID-19: Is the Temptation Worthwhile?. Indian J Crit Care Med 2021; 25 (3):247-248.

DOI: 10.5005/jp-journals-10071-23750

License: CC BY-NC 4.0

Published Online: 01-05-2021

Copyright Statement:  Copyright © 2021; The Author(s).


  1. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis 2020;71(8):1937–1942. DOI: 10.1093/cid/ciaa449.
  2. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474–e484. DOI: 10.1016/S2665-9913(20)30173-9.
  3. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang Lu, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020;ciaa954. DOI: 10.1093/cid/ciaa954.
  4. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020;2(10):e603–e612. DOI: 10.1016/S2665-9913(20)30277-0.
  5. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al; for the STOP-COVID Investigators. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 2021;181(1):41–51. DOI: 10.1001/jamainternmed.2020.6252.
  6. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19(7):102568. DOI: 10.1016/j.autrev.2020.102568.
  7. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al; for the RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard of care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181(1):24–31. DOI: 10.1001/jamainternmed.2020.6615.
  8. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; for the CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181(1):32–40. DOI: 10.1001/jamainternmed.2020.6820.
  9. Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. MedRxiv 2020.08.27.20183442. DOI: 10.1101/2020.08.27.20183442.
  10. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients admitted with Covid-19 pneumonia. N Engl J Med 2021;384:20–30. DOI: 10.1056/NEJMoa2030340.
  11. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383:2333–2344. DOI: 10.1056/NEJMoa2028836.
  12. Rankawat G, Bhandari S, Singh A. Tocilizumab: an effective therapy for severe and critical ill COVID 19 patients. Indian J Crit Care Med 2021;25(3):260–266.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.